CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 286 enrolled
Drug / intervention
Avacincaptad Pegol +1 moredrug
Likely dose
Avacincaptad Pegol 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02686658
NCT02686658Phase 3Completed
CompareCT.gov

A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

IVERIC bio, Inc.·interventional·Posted Feb 19, 2016·Updated Jun 10, 2025

In Brief

A Phase 3 clinical trial evaluating Avacincaptad Pegol and Sham for Geographic Atrophy and Dry Age-Related Macular Degeneration. Completed, enrolled 286 participants across 78 sites in 7 countries.

Detailed Summary

The objectives of this study were to evaluate the safety and efficacy of Zimura intravitreal (IVT) administration when administered in participants with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeographic Atrophy, Dry Age-Related Macular Degeneration
CountriesCroatia, Czechia, Estonia, Hungary, Israel, Latvia, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 19, 2016
Enrollment StartDec 15, 2015
Primary CompletionSep 26, 2019
Study CompletionApr 23, 2020
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 10.4 years ago

Interventions

Avacincaptad Pegoldrug

Avacincaptad Pegol 20 mg/mL solution for intravitreal (IVT) injection

Shamother

The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.